Evidence map›Paper›PMID 35190937›Full record

ReviewBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine2023

Arsenic in medicine: past, present and future.

Ngozi P Paul, Adriana E Galván, Kunie Yoshinaga-Sakurai, Barry P Rosen, Masafumi Yoshinaga

Open access · bronzeAbstract readReview
In one paragraph

Review in Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 1 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. AsRSC advances · 2026
    Article
  4. Article
  5. Review
  6. Synergistic function of ars genes in arsenic detoxification and biosynthesis of organoarsenicals.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. The arsenic proteome in cancer: Unravelling molecular mechanisms of anticancer drugs.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2026
    Review
  11. Article
  12. Inhibition of PHPT1 by phenylarsonic acids.Dalton transactions (Cambridge, England : 2003) · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Arsenome, Arsenobolome, and Arsenobiolome.International journal of molecular sciences · 2025
    Review
  17. Strain-Release Driven Arsenium Ion Bond Insertion.Angewandte Chemie (International ed. in English) · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ngozi P PaulDepartment of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA.
Adriana E GalvánDepartment of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA.
Kunie Yoshinaga-SakuraiDepartment of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA.
Barry P RosenDepartment of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA. brosen@fiu.edu.ORCID http://orcid.org/0000-0002-5230-4271
Masafumi YoshinagaDepartment of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, 33199, USA.
Florida International University · US

Funding

Mechanisms of arsenical transportR37GM055425 · NIGMS · WAYNE STATE UNIVERSITY · PI ROSEN, BARRY P. · 2005 to 2014
$4.4M
Mechanisms of Arsenic Transport and BiotransformationsR01GM055425 · NIGMS · WAYNE STATE UNIVERSITY · PI ROSEN, BARRY P. · 1997 to 2019
$3.8M
MECHANISMS OF ARSENIC TRANSPORT AND BIOTRANSFORMATIONSR35GM136211 · NIGMS · FLORIDA INTERNATIONAL UNIVERSITY · PI ROSEN, BARRY P. · 2020 to 2024
$2.3M
The human arsenic methylation pathwayR01ES023779 · NIEHS · FLORIDA INTERNATIONAL UNIVERSITY · PI ROSEN, BARRY P. · 2015 to 2019
$1.6M
NIEHS NIH HHS R01 ES023779NIGMS NIH HHS R01 GM055425NIGMS NIH HHS R35 GM136211NIH HHS ES023779NIH HHS GM136211NIH HHS GM55425
6 · The paper itself

Abstract

Arsenicals are one of the oldest treatments for a variety of human disorders. Although infamous for its toxicity, arsenic is paradoxically a therapeutic agent that has been used since ancient times for the treatment of multiple diseases. The use of most arsenic-based drugs was abandoned with the discovery of antibiotics in the 1940s, but a few remained in use such as those for the treatment of trypanosomiasis. In the 1970s, arsenic trioxide, the active ingredient in a traditional Chinese medicine, was shown to produce dramatic remission of acute promyelocytic leukemia similar to the effect of all-trans retinoic acid. Since then, there has been a renewed interest in the clinical use of arsenicals. Here the ancient and modern medicinal uses of inorganic and organic arsenicals are reviewed. Included are antimicrobial, antiviral, antiparasitic and anticancer applications. In the face of increasing antibiotic resistance and the emergence of deadly pathogens such as the severe acute respiratory syndrome coronavirus 2, we propose revisiting arsenicals with proven efficacy to combat emerging pathogens. Current advances in science and technology can be employed to design newer arsenical drugs with high therapeutic index. These novel arsenicals can be used in combination with existing drugs or serve as valuable alternatives in the fight against cancer and emerging pathogens. The discovery of the pentavalent arsenic-containing antibiotic arsinothricin, which is effective against multidrug-resistant pathogens, illustrates the future potential of this new class of organoarsenical antibiotics.

Indexed as

ArsenicArsenicalsCOVID-19Anti-Bacterial AgentsHumansOxidesAnti-Bacterial AgentsArsenicArsenicalsOxidesAnticancer drugsAntimicrobialsAntiviralsArsenicMetallodrugsMetalloids

Identifiers

PMID35190937
PMCPMC8860286
OpenAlexW4212861130

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.